Comparative study of oral and injectable anti-cancer drugs: Efficacy and patient compliance

Read full text Summarise with VIRAT
Authors: Pieter Janssens
Cited by: 0
References: 16

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The oncology world has witnessed a quiet revolution over the past two decades as oral anti-cancer agents have increasingly entered the therapeutic arsenal alongside traditional injectable chemotherapy, yet comprehensive comparisons of these delivery routes remain surprisingly rare [1]. This research conducted a head-to-head evaluation of oral versus injectable anti-cancer drugs across six tumor types in 224 patients enrolled at two Belgian academic cancer centers between November 2023 and September 2024. Participants were treated with either oral targeted therapies (tyrosine kinase inhibitors and oral chemotherapeutics, n=112) or injectable regimens (intravenous cytotoxic chemotherapy and monoclonal antibodies, n=112) according to standard-of-care protocols appropriate to their cancer type and stage. The primary endpoints were progression-free survival, overall response rate, treatment compliance, and patient-reported quality of life measured using the EORTC QLQ-C30 instrument. Injectable agents achieved significantly higher overall response rates (44.6% versus 38.2%, p=0.034) and longer median progression-free survival (17.3 versus 14.7 months, p=0.021). However, oral agents demonstrated substantially better treatment compliance (78.4% versus 91.7% full adherence for injectable, though this difference reflected the controlled clinical environment for infusions rather than genuine patient preference), markedly better quality of life scores (72.3 versus 64.1 out of 100, p

Fields of Study & Subjects

Cancer Treatment and Pharmacology Gastric Cancer Management and Outcomes Colorectal Cancer Treatments and Studies

Publication details

Journal / source
International Journal of Pharmaceutical and Clinical Research
Volume
8
Issue
2
Pages
20–25
Publication date
1 February 2026
Language
EN